Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses

INTRODUCTION: Dolutegravir is a second generation integrase inhibitor with a proposed high genetic barrier to resistance. However, in clinical trials, decreased virological response was seen in a subset of patients with prior exposure to raltegravir and multiple integrase resistance mutations. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Marije Hofstra, Laura, Nijhuis, Monique, Mudrikova, Tania, Fun, Axel, Schipper, Pauline, Schneider, Margriet, Wensing, Annemarie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Poster Sessions – Abstract P223
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225339/
https://www.ncbi.nlm.nih.gov/pubmed/25397500
http://dx.doi.org/10.7448/IAS.17.4.19755

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225339/
https://www.ncbi.nlm.nih.gov/pubmed/25397500
http://dx.doi.org/10.7448/IAS.17.4.19755

Ejemplares similares